Work

Phase II trial of SurVaxM combined with standard therapy in patients with newly diagnosed glioblastoma.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.2041

Authors: Manmeet Singh Ahluwalia, David A. Reardon, Ajay P Abad, William T. Curry, Eric T. Wong, Ahmed Belal, Jingxin Qiu, Kathleen Mogensen, Cathy Schilero, Danielle Casucci, Laszlo Mechtler, Erik J Uhlmann, Michael J Ciesielski, Robert Fenstermaker

Institutions: Cleveland Clinic, Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Roswell Park Comprehensive Cancer Center, Massachusetts General Hospital, Beth Israel Deaconess Medical Center, Dent Neurologic Institute

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2889736556

Cites:

Cited by: 3

Related to: 10